Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

Trial Details

NCT ID
NCT05819853
Phase
PHASE3
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Semaglutide Injectable Product (Wegovy and/or Ozempic)
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Ages 12-35 years
  • Sedentary- less than 2 hours of moderate (jogging, swimming etc.) exercise a week.
  • Oligomenorrhea, on or off metformin, as defined per age category in the most recent 2018 PCOS international guidelines
  • Initial BMI based on age and weight:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →